Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
AstraZeneca
CompanyCompany Profile
AstraZeneca is a Swedish-British multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. It was formed in 1999 through the merger of Astra AB and Zeneca Group and maintains a global portfolio across major disease areas.
- Website
- https://www.astrazeneca.com
- Headquarters
- Cambridge, England, UK
- Founded
- 1999
- Stock Ticker
- NYSE:AZN
Related News
Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
AstraZeneca Deepens China Push With COPD Drug License, Lung Cancer Deal and $15bn Investment
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Merck Strengthens Oncology Pipeline as Keytruda Faces 2028 Patent Expiry
Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
China Rises as Pharma R&D Powerhouse While India Pushes Innovation
China has become the dominant source of external drug innovation, with pharma licensing deals reaching $135.7 billion in 2025 and China developing 30% of the world's new innovative drugs. Meanwhile, India is expanding AI use in drug discovery and strengthening its CRDMO and IP infrastructure, though investment gaps persist.
Life Sciences Financing Roundup: $5.7B Buyout, Juvisé Refinancing, Biotech IPO
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
Hengrui Gets NMPA Nod for ADC Phase II Trial, Reports Positive Obesity Data
Hengrui Medicine won NMPA clearance for a Phase II NSCLC trial combining SHR-A2009 ADC with adebrelimab or EGFR-TKI, and with partner Kailera reported up to 12.1% weight loss in a Phase II obesity study of oral ribupatide. SHR-A2009 monotherapy NDA is under review for NSCLC, and cumulative R&D on SHR-A2009 has reached RMB 330 million.
AstraZeneca Reports Strong Q1 2026 Results; Stock Sees Unusual Options Activity
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
Institutional Investors Report Mixed AstraZeneca Holdings Changes in Recent Filings
Groupama Asset Management acquired a new stake in AstraZeneca, while ING Groep NV trimmed its position, reflecting mixed institutional activity. Amundi, Janus Henderson, and Royal Bank of Canada significantly increased their holdings in the first quarter. Institutional investors and hedge funds own 20.35% of AstraZeneca's stock.
Novartis Exits India Unit in $175M Sale to ChrysCapital
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780500 |
REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension |
RECRUITING | |
| NCT07776509 |
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE3 |
| NCT07775404 |
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE3 |
| NCT07774403 |
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization |
RECRUITING | PHASE2 |
| NCT07764978 |
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT |
RECRUITING | PHASE3 |
| NCT07764835 |
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) |
NOT_YET_RECRUITING | |
| NCT07761117 |
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF |
NOT_YET_RECRUITING | PHASE3 |
| NCT07760519 |
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC |
NOT_YET_RECRUITING | |
| NCT07754331 |
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin |
NOT_YET_RECRUITING | PHASE1 |
| NCT07753993 |
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. |
NOT_YET_RECRUITING | PHASE3 |